14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs SNY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over Sanofi (SNY) on higher Unified Composite conviction (41.5/100 SELL vs. 31.7/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while SNY wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus SNY at $48.61 (8.9x Forward P/E, 22.3% operating margin).
Growth vs. Quality Trade-Off: NVS earns the overall head-to-head edge with a stronger Unified Composite Score (41.5/100 SELL vs. SNY 31.7/100 SELL) and 0.31β · 27% Vol risk profile, whereas SNY leads top-line expansion (+15.7% YoY revenue growth, 1.76x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although NVS compares more favorably head-to-head, both NVS (41.5/100 SELL) and SNY (31.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs SNY. Trailing 12-month operating profitability (NVS 34.0% vs SNY 22.3%) and valuation multiples (NVS 16.2x vs SNY 8.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
SNY Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $116.0B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment52.0% of Rev ($15.6B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs SNY Key Questions & Quantitative Answers
As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over Sanofi (SNY) on higher Unified Composite conviction (41.5/100 SELL vs. 31.7/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while SNY wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus SNY at $48.61 (8.9x Forward P/E, 22.3% operating margin). Growth vs. Quality Trade-Off: NVS earns the overall head-to-head edge with a stronger Unified Composite Score (41.5/100 SELL vs. SNY 31.7/100 SELL) and 0.31β · 27% Vol risk profile, whereas SNY leads top-line expansion (+15.7% YoY revenue growth, 1.76x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although NVS compares more favorably head-to-head, both NVS (41.5/100 SELL) and SNY (31.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SNY leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with SNY at +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.0B TTM revenue (74.3% gross margin, 22.3% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $30.0B for SNY. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 52.0% of Rev ($15.6B) (0 disclosures) for SNY.
SNY screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas SNY trades at 8.9x Forward P/E, 24.1x Trailing P/E, 1.76x PEG, and 3.9x EV/Revenue (29.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus SNY (5.7% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.21β · 27% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.